A Trial to Assess the Efficacy and Safety of Medical Grade Cannabis in Children Diagnosed With Autism Spectrum Disorder
Status:
Withdrawn
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
This single center, double-blinded, randomized, placebo-controlled crossover trial will
assess the efficacy and safety of extraction of cannabis flowers dissolved in olive oil (30%
CBD and 1.5% Δ9-THC) vs. placebo in patients diagnosed with Autism Spectrum Disorder. The
trial will contain two phases in which patients will first receive a twelve-week treatment of
either cannabis or placebo followed by four weeks wash out period and another twelve weeks of
crossover in the trial arms.